Emergent BioSolutions Secures FDA OK for 6-Count and 24-Count NARCAN Multipacks
Emergent BioSolutions won FDA approval for over-the-counter NARCAN Nasal Spray in new 6-count and 24-count multipacks, expanding options for high-volume naloxone distributors. EBS represents approximately 0.33% of the Schwab Fundamental U.S. Small Company ETF, which may modestly benefit from increased naloxone sales after over 85 million doses distributed.
1. FDA Approval for New NARCAN Multipacks
Emergent BioSolutions received supplemental New Drug Application approval for 6-count and 24-count multipacks of its over-the-counter 4 mg NARCAN Naloxone Nasal Spray, the first of its kind for emergency opioid overdose treatment. The approval aims to provide greater flexibility for distributors handling large-volume naloxone orders.
2. Implications for Emergent BioSolutions Sales
Since NARCAN launch in 2016, over 85 million doses have been distributed across the U.S. and Canada, highlighting robust demand. The new multipack configurations are expected to bolster naloxone revenue streams as partners leverage the proprietary NARCANDirect ordering platform for bulk purchasing.
3. Impact on FNDA ETF Exposure
Emergent BioSolutions makes up roughly 0.33% of the Schwab Fundamental U.S. Small Company ETF (FNDA). While EBS is a small holding within the ETF, enhanced naloxone distribution and sales momentum could provide a modest uplift to FNDA’s overall performance.